Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemispheric Clear all
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 22, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

A Drug-drug Interaction Study of Avapritinib and Midazolam

NCT04908176
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
Interventions
Avapritinib, midazolam
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 22, 2026, 4:48 PM EDT
Active, not recruiting Not applicable Interventional

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03739372
View directory record Official record
Conditions
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions
Specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 22, 2026, 4:48 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

NCT07389278
View directory record Official record
Conditions
Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Hemispheric Glioma, H3G34 Mutant
Interventions
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 39 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Completed No phase listed Observational

Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology

NCT03148340
View directory record Official record
Conditions
Stroke, Stroke, Acute, Ischemic Stroke, Hemorrhage, Clot (Blood); Brain, Subarachnoid Hemorrhage, Cerebral Infarction, Cerebral Hemorrhage, Cerebral Stroke, Intracerebral Hemorrhage, Intracerebral Injury
Interventions
VIPS Monitoring
Diagnostic Test
Lead sponsor
Cerebrotech Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Jacksonville, Florida • Buffalo, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jul 22, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant, Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions
Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Triapine
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Duarte, California • Irvine, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Terminated Not applicable Interventional Results available

A Study to Detect Progression of Mass Effect From Unilateral Brain Lesions

NCT04745884
View directory record Official record
Conditions
Non-traumatic Hemispheric Brain Lesions
Interventions
Non-invasive bilateral monitoring of ICP waveform
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953
View directory record Official record
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Jul 22, 2026, 4:48 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sedline 4 Channel Electroencephalogram (EEG) Monitoring During Suppression of Unilateral Hemispheric Function (Wada Test

NCT02503878
View directory record Official record
Conditions
Seizure
Interventions
Masimo Sedline brain function monitors
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 22, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

NCT06914479
View directory record Official record
Conditions
Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm
Interventions
Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection, Magnetic Resonance Imaging, Survey Administration, Tumor Resection, Valacyclovir
Genetic · Procedure · Other + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Areas of Brain Responsible for Understanding American Sign Language

NCT00001782
View directory record Official record
Conditions
Brain Mapping, Deafness, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 4:48 PM EDT
Recruiting Phase 2 Interventional

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

NCT05843253
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Ribociclib, Everolimus, Temozolomide (TMZ)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

NCT06333899
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
Interventions
Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Withdrawn Not applicable Interventional

Functional Connectivity and Predictors of Affective Aprosodia Intervention in Subacute Right Hemisphere Stroke

NCT04575909
View directory record Official record
Conditions
Right Hemispheric Stroke
Interventions
Aprosodia Intervention, No-Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 22, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

A Study of 177Lu-PSMA-617 in People With Gliomas

NCT07223034
View directory record Official record
Conditions
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
Interventions
Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI, Quality of Life Questionnaires
Drug · Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Active, not recruiting Phase 1 Interventional

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

NCT06342908
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Biospecimen Collection, Dendritic Cell Therapy, Leukapheresis, Magnetic Resonance Imaging, Poly ICLC
Procedure · Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 4:48 PM EDT
Enrolling by invitation Phase 1 Interventional

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

NCT06896110
View directory record Official record
Conditions
Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant, Gliosarcoma of Brain
Interventions
Nivolumab, Azacitidine (AZA), lumbar puncture, MRI Contrast
Drug · Procedure · Diagnostic Test
Lead sponsor
Andrew P. Groves
Other
Eligibility
13 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jul 22, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional

Transcranial Direct Current Stimulation (TDCS) for Facilitating Swallowing Improvement After an Acute Unilateral Hemispheric Stroke

NCT01132066
View directory record Official record
Conditions
Dysphagia
Interventions
tDCS, Sham
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Jul 22, 2026, 4:48 PM EDT
Completed No phase listed Observational

Studying Use-Dependent Plasticity

NCT00067223
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 4:48 PM EDT